Tag
Anil Satwani
2 articles
Symbiotec Pharmalab Q2 PAT Surges 169% YoY
Symbiotec Pharmalab reported 43% YoY revenue growth and 169% PAT growth in Q2FY27 driven by strong API performance and milestone revenue from complex injectables.
Company secured multiple regulatory a
Symbiotec Pharmalab Q2 Revenue Up 43% YoY
Submitted Q2 & H1FY27 investor presentation to BSE and NSE pursuant to SEBI Listing Regulation 30.
Reported consolidated Q2FY27 revenue of ₹280 crs, up 43% YoY, with PAT surging 169% to ₹52 crs.
Recog